<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01906632</url>
  </required_header>
  <id_info>
    <org_study_id>GIMC</org_study_id>
    <nct_id>NCT01906632</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate gene expression profile and immunological associated analysis relating to&#xD;
      immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine&#xD;
           induced killer cells (CIK) .&#xD;
&#xD;
        2. Venous blood (4 ml) is collected from each subject and placed into tubes containing&#xD;
           Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are&#xD;
           sorted by Fluorescence Activated Cell Sorting(FACS) and stored at -80°C until&#xD;
           processing.&#xD;
&#xD;
        3. The T-Cell Receptor/B-Cell Receptor gene expression is detected by micro-array。&#xD;
&#xD;
        4. Estimate Immunotherapy response, time to disease progression, survival rates and&#xD;
           clinical benefit response on patients. Response is assessed using Response Evaluation&#xD;
           Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide&#xD;
           the cancers into two groups: sensitive and non-sensitive to immunotherapy.&#xD;
&#xD;
        5. Compare the gene expression profile between different immunotherapy response groups to&#xD;
           explore the mechanism that predict the DC-CIK immunotherapy response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T-Cell Receptor/B-Cell Receptor gene expression</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>gene expression profile</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC-CIK Immunotherapy</intervention_name>
    <arm_group_label>gene expression profile</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed with malignant tumor;&#xD;
&#xD;
          -  Age: 18-80 years;&#xD;
&#xD;
          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;&#xD;
&#xD;
          -  At least one measurable lesion according to the RECIST criteria;&#xD;
&#xD;
          -  Adequate bone marrow, cardiac, liver, and renal function;&#xD;
&#xD;
          -  Life expectancy ≥2 months;&#xD;
&#xD;
          -  Not received other anti-tumor treatment&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous history of other malignancies;&#xD;
&#xD;
          -  Uncontrolled central nervous system metastases;&#xD;
&#xD;
          -  Serious or uncontrolled concurrent medical illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Ren, MD, PhD</last_name>
    <phone>86-10-63926317</phone>
    <email>renjun9688@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ren, MD, PhD</last_name>
      <phone>86-10-63926317</phone>
      <email>renjun9688@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 21, 2013</study_first_submitted>
  <study_first_submitted_qc>July 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jun Ren MD, PhD</investigator_full_name>
    <investigator_title>Director, Capita Medical University Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

